Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis
- PMID: 16322474
- DOI: 10.1182/blood-2005-04-1758
Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis
Abstract
Classical von Willebrand disease (VWD) type 2A, the most common qualitative defect of VWD, is caused by loss of high-molecular-weight multimers (HMWMs) of von Willebrand factor (VWF). Underlying mutations cluster in the A2 domain of VWF around its cleavage site for ADAMTS13. We investigated the impact of mutations commonly found in patients with VWD type 2A on ADAMTS13-dependent proteolysis of VWF. We used recombinant human ADAMTS13 (rhuADAMTS13) to digest recombinant full-length VWF and a VWF fragment spanning the VWF A1 through A3 domains, harboring 13 different VWD type 2A mutations (C1272S, G1505E, G1505R, S1506L, M1528V, R1569del, R1597W, V1607D, G1609R, I1628T, G1629E, G1631D, and E1638K). With the exception of G1505E and I1628T, all mutations in the VWF A2 domain increased specific proteolysis of VWF independent of the expression level. Proteolytic susceptibility of mutant VWF in vitro closely correlated with the in vivo phenotype in patients. The results imply that increased VWF susceptibility for ADAMTS13 is a constitutive property of classical VWD type 2A, thus explaining the pronounced proteolytic fragments and loss of HMWM seen in multimer analysis in patients.
Similar articles
-
A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.J Thromb Haemost. 2004 Jul;2(7):1135-42. doi: 10.1111/j.1538-7836.2004.00732.x. J Thromb Haemost. 2004. PMID: 15219197
-
Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.Acta Haematol. 2009;121(2-3):154-66. doi: 10.1159/000214856. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506362 Review.
-
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.Thromb Haemost. 2013 Jun;109(6):999-1006. doi: 10.1160/TH12-11-0808. Epub 2013 Feb 28. Thromb Haemost. 2013. PMID: 23446343
-
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.J Mol Model. 2004 Aug;10(4):259-70. doi: 10.1007/s00894-004-0194-9. Epub 2004 Aug 3. J Mol Model. 2004. PMID: 15322948
-
Molecular genetics of type 2 von Willebrand disease.Int J Hematol. 2002 Jan;75(1):9-18. doi: 10.1007/BF02981973. Int J Hematol. 2002. PMID: 11843298 Review.
Cited by
-
The molecular genetics of von Willebrand disease.Turk J Haematol. 2012 Dec;29(4):313-24. doi: 10.5505/tjh.2012.39205. Epub 2012 Dec 5. Turk J Haematol. 2012. PMID: 24385719 Free PMC article. Review.
-
Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.J Thromb Haemost. 2016 Sep;14(9):1725-35. doi: 10.1111/jth.13398. Epub 2016 Aug 20. J Thromb Haemost. 2016. PMID: 27344059 Free PMC article.
-
The activity of the intrinsically water-soluble enzyme ADAMTS13 correlates with the membrane state when bound to a phospholipid bilayer.Sci Rep. 2021 Dec 28;11(1):24476. doi: 10.1038/s41598-021-04083-0. Sci Rep. 2021. PMID: 34963692 Free PMC article.
-
ADAMTS-13 and von Willebrand factor: a dynamic duo.J Thromb Haemost. 2018 Jan;16(1):6-18. doi: 10.1111/jth.13898. Epub 2017 Dec 2. J Thromb Haemost. 2018. PMID: 29108103 Free PMC article. Review.
-
Mechanistic studies on ADAMTS13 catalysis.Biophys J. 2008 Sep;95(5):2450-61. doi: 10.1529/biophysj.108.131532. Epub 2008 May 23. Biophys J. 2008. PMID: 18502798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
